https://www.openbell.ai/ 2026-10-16T16:48:03.042Z hourly 1.0 https://www.openbell.ai/support 2026-10-16T16:48:03.042Z monthly 0.7 https://www.openbell.ai/privacy 2026-10-16T16:48:03.042Z monthly 0.5 https://www.openbell.ai/terms 2026-10-16T16:48:03.042Z monthly 0.5 https://www.openbell.ai/feed.json 2026-10-16T16:48:03.042Z hourly 0.8 https://www.openbell.ai/news/AI:1792169139087 2026-10-16T16:45:39.087Z daily 0.9 https://cdn.brandfetch.io/AI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of software companies are trading lower amid a rotation out of technology and AI-related stocks. Rising inflation concerns and elevated oil prices are fueling expectations for further Fed tightening, while elevated borrowing costs could weigh on demand, valuations and debt metrics. openbell Financial News https://www.openbell.ai/news/USB:1792169112479 2026-10-16T16:45:12.479Z daily 0.9 https://cdn.brandfetch.io/USB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is U.S. Bancorp Stock Gaining Friday? U.S. Bancorp (NYSE: USB) stock rose 1.71% to $58.37 following a bullish report from D.A. Davidson, which maintained a Buy rating and a price target of $73. The bank reported third-quarter earnings of $1.34 per share, exceeding estimates, with revenue increasing 10.9% year-over-year. Additionally, U.S. Bancorp's partnership with Amazon, which includes a $1.7 billion small-business credit card portfolio, is expected to generate $75 million to $85 million in quarterly revenue, further supporting its growth outlook. https://www.openbell.ai/news/USB:1792169090451 2026-10-16T16:44:50.451Z daily 0.9 https://cdn.brandfetch.io/USB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is U.S. Bancorp Stock Gaining Friday? U.S. Bancorp (NYSE: USB) stock is rising, supported by D.A. Davidson's bullish outlook, which includes a Buy rating and a price target of $73. The bank reported third-quarter earnings of $1.34 per share, exceeding estimates, with revenue growth of 10.9% year-over-year and net interest income of $4.49 billion. Additionally, U.S. Bancorp's recent acquisition of Amazon's $1.7 billion small-business credit card portfolio is expected to generate significant quarterly revenue, further enhancing its profitability outlook. https://www.openbell.ai/news/BNY:1792168923399 2026-10-16T16:42:03.399Z daily 0.9 https://cdn.brandfetch.io/BNY/w/400/h/400?c=1idopYfmtR7ZKg8QMud BNY’s Transformation ‘Continues to Deliver Strong Results,’ Analyst Says After Q3 Beat Bank of New York Mellon Corp (NYSE: BNY) reported a 12% year-on-year revenue growth to $5.68 billion in Q3, driven by a 12% increase in fee revenue and a notable 43% growth in Issuer Services. Earnings rose 24% to $2.34 per share, exceeding the consensus estimate of $2.27. The company returned $1.37 billion to shareholders through dividends and share repurchases, with a year-to-date payout ratio of 86%. Following the results, BNY shares rose 0.78% to $143.20. https://www.openbell.ai/news/QTWO:1792168922850 2026-10-16T16:42:02.850Z daily 0.9 https://cdn.brandfetch.io/QTWO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stephens & Co. Reinstates Overweight on Q2 Holdings, Announces $74 Price Target Stephens & Co. analyst Brett Huff has reinstated an Overweight rating on Q2 Holdings (NYSE: QTWO) and set a price target of $74 for the stock. This marks a positive outlook for the company in the market. https://www.openbell.ai/news/CIFR:1792168863565 2026-10-16T16:41:03.565Z daily 0.9 https://cdn.brandfetch.io/CIFR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is Cipher Digital Stock Falling on Friday? Cipher Digital Inc (NASDAQ: CIFR) stock is down 8.17% at $9.22 amid broader declines in AI cloud services stocks due to concerns over the debt required for AI infrastructure. A warning from Gartner regarding the sustainability of spending on AI computing capacity has negatively impacted market sentiment. Additionally, the stock is trading significantly below its 20-day and 200-day simple moving averages, indicating a bearish trend, and is currently testing key support levels around $9.80. https://www.openbell.ai/news/NCNO:1792168633144 2026-10-16T16:37:13.144Z daily 0.9 https://cdn.brandfetch.io/NCNO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stephens & Co. Reinstates Overweight on Ncino, Announces $26 Price Target Stephens & Co. analyst Brett Huff has reinstated an Overweight rating on Ncino (NASDAQ: NCNO) and set a price target of $26 for the stock. This strategic move indicates a positive outlook for Ncino's performance in the market. https://www.openbell.ai/news/MU:1792168386335 2026-10-16T16:33:06.335Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/New-York--Ny--Usa---11-05-2024-Wall-Stre.jpg?width=250&height=187 Nasdaq 100 Slides As Micron, SanDisk, CoreWeave Sink: Stock Market Today On Friday, the Nasdaq 100 fell 1.3%, or 400 points, to approximately 29,535, primarily due to declines in AI-related stocks, including CoreWeave Inc. which dropped 9.3%. Micron Technology Inc. and SanDisk Corp. also saw losses of 3.6% and 4.2%, respectively. Meanwhile, the Dow Jones Industrial Average gained 150 points, or 0.3%, to around 52,328, as investors rotated into value and defensive stocks amid ongoing concerns over AI infrastructure debt. https://www.openbell.ai/news/ABBV:1792168290860 2026-10-16T16:31:30.860Z daily 0.9 https://cdn.brandfetch.io/ABBV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Live On CNBC, Kevin Simpson Announces Bought AbbVie openbell Financial News https://www.openbell.ai/news/FOX:1792168156319 2026-10-16T16:29:16.319Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Konskie--Poland---January-27--2024-Fox-C.jpg?width=250&height=187 Fox's Roku Deal 'Fundamentally Changes' the Game, Analyst Upgrades Stock to Buy Fox Corp. (NASDAQ: FOXA) has been upgraded by Bank of America from Underperform to Buy, with a price target increase from $54 to $85, due to the anticipated growth from its acquisition of Roku, Inc. The deal, expected to close in early 2027, is projected to generate approximately $530 million in additional annual revenue and $400 million in cost savings by 2028, potentially adding nearly $700 million to annual EBITDA. Fox shares rose 1.24% to $57.85 following the announcement. https://www.openbell.ai/news/XOM:1792168023604 2026-10-16T16:27:03.604Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Channahon--Illinois--Usa--June-7-2022-Ex.jpg?width=250&height=187 ExxonMobil Sees $4.5 Billion Boost from Higher Refining Margins ExxonMobil (NYSE: XOM) anticipates a $4.5 billion increase in third-quarter Energy Products earnings due to higher refining margins. However, the company also expects a $1.3 billion earnings headwind from lower liquids prices in its Upstream segment, partially offset by a $300 million benefit from gas price changes. Analysts project earnings per share (EPS) of $3.83 and revenue of $102.02 billion for the upcoming earnings report on October 30, 2026, with the stock currently trading at $176.41. https://www.openbell.ai/news/PLD:1792167688619 2026-10-16T16:21:28.619Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Prologis-Sign--Logo-On-Business-Facade-O.jpg?width=250&height=187 Prologis Analyst Touts ‘Ample Defenses’ Against Data Center Challenges Prologis, Inc. (NYSE: PLD) shares closed nearly 3% lower after reporting third-quarter results, with a fourth-quarter FFO guidance of $1.54 per share, falling 3 cents below consensus. Analyst Thomas Catherwood maintained a Buy rating with a price target of $170, citing strong U.S. demand and a decrease in vacancy rates to 7.1%. The company is raising rents in about 30% of its markets, up from 10% a year ago, with notable growth in regions like Dallas and Northern California. Despite challenges in the data center sector, Prologis's development strategy and access to capital are viewed as strong defenses. https://www.openbell.ai/news/JNJ:1792166864248 2026-10-16T16:07:44.248Z daily 0.9 https://cdn.brandfetch.io/JNJ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $287 Wells Fargo analyst Larry Biegelsen has maintained an Overweight rating on Johnson & Johnson (NYSE: JNJ) and raised the price target from $275 to $287. This adjustment reflects a positive outlook for the company's stock performance. https://www.openbell.ai/news/REAL:1792166688668 2026-10-16T16:04:48.668Z daily 0.9 https://cdn.brandfetch.io/REAL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Roth Capital Reiterates Buy on RealReal, Maintains $19 Price Target Roth Capital analyst Matt Koranda has reiterated a Buy rating on RealReal (NASDAQ: REAL) and maintained a price target of $19 for the stock. This endorsement suggests confidence in the company's performance and potential for growth. https://www.openbell.ai/news/F:1792166559644 2026-10-16T16:02:39.644Z daily 0.9 https://cdn.brandfetch.io/F/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ford Motor shares are trading higher after Zachs Equity Research called the company a "strong value stock." openbell Financial News https://www.openbell.ai/news/AMD:1792166553528 2026-10-16T16:02:33.528Z daily 0.9 https://cdn.brandfetch.io/AMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of semiconductor and chip companies are trading lower as rising inflation concerns and elevated energy prices fuel expectations for further Fed rate hikes. Elevated borrowing costs could pressure semiconductor manufacturing and AI infrastructure investments while straining customer budgets. The Philadelphia Semiconductor Index (SOX) has declined for seven consecutive trading sessions, matching its longest losing streak since the 2008 financial crisis. openbell Financial News https://www.openbell.ai/news/IRD:1792166535698 2026-10-16T16:02:15.698Z daily 0.9 https://cdn.brandfetch.io/IRD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Opus Genetics Receives FDA Approval For Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% To Treat Presbyopia In Adults Opus Genetics, Inc. has received FDA approval for its supplemental New Drug Application for phentolamine ophthalmic solution 0.75% to treat presbyopia in adults. This approval will result in a milestone payment to Opus Genetics as part of its global licensing agreement with Viatris Inc., which grants Viatris exclusive rights to commercialize the product in the U.S. https://www.openbell.ai/news/MU:1792166488026 2026-10-16T16:01:28.026Z daily 0.9 https://cdn.brandfetch.io/MU/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of memory- and storage-related chip companies are trading lower amid continued weakness as investors weigh intensifying Chinese competition and concerns over possible market oversupply. Rising inflation concerns and elevated energy prices are fueling expectations for further Fed rate hikes, which could increase borrowing costs and weigh on demand across the sector. openbell Financial News https://www.openbell.ai/news/META:1792166441679 2026-10-16T16:00:41.679Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Meta-And-Other-Social-Media-Giants-Ask-F.jpg?width=250&height=187 Meta's AI Bet Could Deliver Another Earnings Surprise, Analyst Says Meta Platforms Inc. is expected to report third-quarter revenue of $63.8 billion, surpassing Wall Street's estimate of $63.3 billion, driven by strong advertising demand and AI improvements. However, the company's earnings estimate has been lowered from $7.08 to $3.79 per share due to a $10 billion legal accrual, which is below the consensus of $6.08. Bank of America also raised its 2027 capital expenditure forecast for Meta to $205 billion, reflecting increased investment in AI infrastructure. Despite a recent 2.17% decline in stock price to $720.71, analysts maintain a consensus Buy rating on Meta. https://www.openbell.ai/news/META:1792166369506 2026-10-16T15:59:29.506Z daily 0.9 https://cdn.brandfetch.io/META/w/400/h/400?c=1idopYfmtR7ZKg8QMud Meta's AI Bet Could Deliver Another Earnings Surprise, Analyst Says Meta Platforms Inc. is expected to report third-quarter revenue of $63.8 billion, surpassing Wall Street's estimate of $63.3 billion, driven by strong advertising demand and AI improvements. However, the firm's earnings estimate has been lowered from $7.08 to $3.79 per share due to a one-time $10 billion legal accrual, below the consensus of $6.08. Bank of America also raised its 2027 capital expenditure forecast to $205 billion, reflecting increased investment in AI infrastructure. Meta's stock was down 2.17% to $720.71 ahead of its earnings report on October 21. https://www.openbell.ai/news/MU:1792166347494 2026-10-16T15:59:07.494Z daily 0.9 https://cdn.brandfetch.io/MU/w/400/h/400?c=1idopYfmtR7ZKg8QMud Micron, SK Hynix Have an AI Boom Problem — China Could Make It Worse Shares of Micron Technology, Inc. (NASDAQ: MU) and SK Hynix Inc. (NASDAQ: SKHY) fell significantly, with Micron down about 10% and SK Hynix nearly 15%, following advancements by Chinese memory maker ChangXin Memory Technologies (CXMT) in DRAM chip technology. CXMT's new 4F-squared architecture could enhance production efficiency, raising concerns about increased competition in the memory market. Micron's CEO announced that capital expenditures would exceed $25 billion in fiscal 2026 to expand HBM and DRAM capacity, while analysts noted that CXMT's manufacturing process is still behind industry leaders, potentially delaying mass production until 2028. https://www.openbell.ai/news/USB:1792166103974 2026-10-16T15:55:03.974Z daily 0.9 https://cdn.brandfetch.io/USB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Evercore ISI Group Maintains Outperform on U.S. Bancorp, Raises Price Target to $67 Evercore ISI Group analyst Vijay Kumar has maintained an 'Outperform' rating on U.S. Bancorp (NYSE: USB) and increased the price target from $65 to $67. This adjustment reflects a positive outlook for the company's performance in the market. https://www.openbell.ai/news/IBRX:1792165912582 2026-10-16T15:51:52.582Z daily 0.9 https://cdn.brandfetch.io/IBRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud ImmunityBio Announces Data From Its Phase 2/3 QUILT-3.032 Trial Of ANKTIVA In Combination With Bacillus Calmette-Guerin Demonstrates 71% Complete Response Rate In Participants With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ ImmunityBio, Inc. announced long-term data from its Phase 2/3 QUILT-3.032 trial, revealing a 71% complete response rate for its treatment ANKTIVA in patients with BCG-unresponsive non-muscle invasive bladder cancer. The median duration of complete response was 26.6 months, with some responses lasting over 53 months. Additionally, the study reported an 84% cystectomy-free survival rate at 36 months and a 98.2% disease-specific survival rate at three years, with no severe treatment-related adverse events noted. https://www.openbell.ai/news/SPCX:1792165723000 2026-10-16T15:48:43.000Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Rocket-Launch-A-Spacex-Falcon-Heavy-Rock.jpg?width=250&height=187 SpaceX Q3 Earnings Countdown: 5 Debates to Watch SpaceX (NASDAQ: SPCX) is set to release its Q3 financial results on October 20, 2026, with an audio webcast scheduled for 4:30 p.m. ET. Analyst Kutgun Maral from Evercore ISI has raised his price target for the stock from $230 to $275, indicating an 85% upside potential. He anticipates a significant revenue increase, projecting annualized revenue to exceed $100 billion by the end of 2026, driven by strategic compute deals and growth in AI and connectivity sectors. As of the latest report, SpaceX's stock was down 1.81%, trading at $145.93. https://www.openbell.ai/news/WSE:1792165296404 2026-10-16T15:41:36.404Z daily 0.9 https://cdn.brandfetch.io/WSE/w/400/h/400?c=1idopYfmtR7ZKg8QMud JP Morgan Maintains Overweight on Wise Group, Raises Price Target to $17.7 JP Morgan analyst Craig McDowell has maintained an Overweight rating on Wise Group (NASDAQ: WSE) and raised the price target from $17.3 to $17.7. This adjustment reflects a positive outlook for the company. https://www.openbell.ai/news/SPY:1792165182353 2026-10-16T15:39:42.353Z daily 0.9 https://cdn.brandfetch.io/SPY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barclays Expects U.S. Fed To Deliver A 25 BP Rate Hike Each In December And January Vs Prior Forecast Of A Hike In December This Year Barclays has revised its forecast for U.S. Federal Reserve interest rate hikes, now expecting a 25 basis point increase in both December 2023 and January 2024, compared to its previous prediction of a single hike in December. This change reflects Barclays' updated outlook on monetary policy and its implications for the market. https://www.openbell.ai/news/TRV:1792165141107 2026-10-16T15:39:01.107Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Travelers-Companies.jpg?width=250&height=187 Travelers Companies Stock Is Gaining Friday: What's Going On? Travelers Companies Inc. (NYSE: TRV) reported strong third-quarter results, with adjusted earnings of $9.18 per share surpassing the analyst estimate of $7.42, while revenue fell slightly to $12.41 billion, exceeding expectations of $11.38 billion. The company returned $1.8 billion to shareholders through share repurchases and dividends, and its adjusted book value per share increased by 15% to $172.47. Despite a rise in catastrophe losses to $538 million, the combined ratio improved to 86.8%, indicating an underwriting profit. As of Friday, Travelers shares were up 1.01% at $387.76, nearing its 52-week high of $398.69. https://www.openbell.ai/news/RIOT:1792164651592 2026-10-16T15:30:51.592Z daily 0.9 https://cdn.brandfetch.io/RIOT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of AI cloud services companies are trading lower amid persistent concerns over the debt required to sustain the AI infrastructure buildout. Sentiment is also under pressure following a Gartner warning about the outlook for neocloud providers, fueling concerns over the sustainability of spending on AI computing capacity. openbell Financial News https://www.openbell.ai/news/UNH:1792164645467 2026-10-16T15:30:45.467Z daily 0.9 https://cdn.brandfetch.io/UNH/w/400/h/400?c=1idopYfmtR7ZKg8QMud JP Morgan Maintains Overweight on UnitedHealth Group, Raises Price Target to $524 JP Morgan analyst Lisa Gill has maintained an Overweight rating on UnitedHealth Group (NYSE: UNH) and increased the price target from $516 to $524. This adjustment reflects a positive outlook for the company in the market. https://www.openbell.ai/news/APLD:1792164071477 2026-10-16T15:21:11.477Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/The-Applied-Digital-Corporation-Logo-Is-.jpg?width=250&height=187 Why Is Applied Digital Stock Falling Friday? Applied Digital Corp. (NASDAQ: APLD) experienced a 7.21% decline in stock price, trading at $18.92, amid concerns over AI infrastructure financing costs and a broader sell-off in AI data-center stocks. The Nasdaq index fell by 0.68%, while the S&P 500 saw a slight gain of 0.07%. The downturn is linked to rising debt levels and high bond yields, particularly following CoreWeave Inc.'s bond issue, which saw yields peak at 15%. Technical indicators show that APLD is trading significantly below its major moving averages, indicating a bearish trend. https://www.openbell.ai/news/AAPG:1792163607565 2026-10-16T15:13:27.565Z daily 0.9 https://cdn.brandfetch.io/AAPG/w/400/h/400?c=1idopYfmtR7ZKg8QMud William Blair Initiates Coverage On Ascentage Pharma Group with Outperform Rating William Blair analyst Alethia Young has initiated coverage on Ascentage Pharma Group (NASDAQ: AAPG) with an Outperform rating. This marks a positive outlook for the company in the market. https://www.openbell.ai/news/EW:1792163587622 2026-10-16T15:13:07.622Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Irvine--California---7-May-2023-Edwards-.jpg?width=250&height=187 FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death The FDA has issued a high-risk alert regarding a recall of specific lots of Edwards Lifesciences' Commander M delivery systems after reports of balloons bursting during procedures, which resulted in one patient death and a serious injury. The company has advised customers to stop using the affected products and to coordinate returns with company representatives. As a result of the recall, Edwards Lifesciences' stock price fell by 0.86% to $87.34. https://www.openbell.ai/news/SKHY:1792163504141 2026-10-16T15:11:44.141Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Benzinga-Quick-Spark.jpg?width=250&height=187 QUICK SPARK: South Korea’s KOSPI Logs Worst Week Since 2008’s Lehman Brothers Collapse The KOSPI index in South Korea experienced a significant decline of 14.46% for the week, marking its worst performance since the Lehman Brothers collapse in October 2008. Notably, SK Hynix Inc. fell 24.3% and Samsung Electronics Co. Ltd. dropped 17.8%, both reflecting their steepest weekly losses since that period. The KOSPI is currently 37.8% below its record close of 9,114.55, despite being up 34.5% in 2026. Additionally, the iShares MSCI South Korea ETF was down over 13% during Friday trading. https://www.openbell.ai/news/WDAY:1792163434182 2026-10-16T15:10:34.182Z daily 0.9 https://cdn.brandfetch.io/WDAY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Workday shares are trading lower after Keybanc downgraded the stock from Overweight to Sector Perform. openbell Financial News https://www.openbell.ai/news/RKLB:1792163257072 2026-10-16T15:07:37.072Z daily 0.9 https://cdn.brandfetch.io/RKLB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Rocket Lab shares are trading lower after Citizens lowered its price target on the stock from $130 to $90. openbell Financial News https://www.openbell.ai/news/EWTX:1792163152572 2026-10-16T15:05:52.572Z daily 0.9 https://cdn.brandfetch.io/EWTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating William Blair analyst Alethia Young has initiated coverage on Edgewise Therapeutics (NASDAQ: EWTX) with an Outperform rating. This marks a positive outlook for the company in the market. https://www.openbell.ai/news/HUT:1792163094722 2026-10-16T15:04:54.722Z daily 0.9 https://cdn.brandfetch.io/HUT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Hut 8 shares are trading lower after Cantor Fitzgerald lowered its price target on the stock from $180 to $151. openbell Financial News https://www.openbell.ai/news/LLY:1792163071799 2026-10-16T15:04:31.799Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Los-Angeles--California---July-7-2025-El.jpg?width=250&height=187 Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes Eli Lilly and Co's new medication, Foundayo, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for marketing authorization in Europe, aimed at treating type 2 diabetes and aiding weight management. Foundayo, which contains the active ingredient orforglipron, is indicated for adults with obesity or overweight conditions alongside diet and exercise. Following the announcement, Eli Lilly's stock rose by 1.44% to $1269.60, nearing its 52-week high of $1292.65. https://www.openbell.ai/news/JKHY:1792163013340 2026-10-16T15:03:33.340Z daily 0.9 https://cdn.brandfetch.io/JKHY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jack Henry To Provide Tokenized Deposits Under Expanded Partnership With Google Cloud Through Universal Ledger Jack Henry (NASDAQ: JKHY) has announced an expansion of its partnership with Google Cloud to provide tokenized deposits through the Google Cloud Universal Ledger (GCUL). This collaboration positions Jack Henry as the first core technology provider to integrate with GCUL, enabling banks and credit unions to modernize their deposit offerings and enhance customer relationships. GCUL is a managed distributed ledger service that allows financial institutions to tokenize and transfer assets with real-time settlement capabilities. https://www.openbell.ai/news/RVMD:1792162969433 2026-10-16T15:02:49.433Z daily 0.9 https://cdn.brandfetch.io/RVMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud William Blair Initiates Coverage On Revolution Medicines with Outperform Rating William Blair analyst Alethia Young has initiated coverage on Revolution Medicines (NASDAQ: RVMD) with an Outperform rating. This marks a positive outlook for the company as it enters a new phase of market analysis. https://www.openbell.ai/news/PSX:1792162945267 2026-10-16T15:02:25.267Z daily 0.9 https://cdn.brandfetch.io/PSX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Phillips 66 Raises Quarterly Dividend From $1.27 To $1.33 Per Share Phillips 66 (NYSE: PSX) has announced an increase in its quarterly dividend from $1.27 to $1.33 per share, marking a $0.06 increase. The new dividend will be payable on December 1, 2026, to shareholders on record as of November 17, 2026. https://www.openbell.ai/news/SPY:1792162820453 2026-10-16T15:00:20.453Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Charts-Of-Financial-Instruments-With-Var.jpg?width=250&height=187 9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead On Friday, nine of the eleven sectors in the market experienced gains, with the Materials sector leading at +1.62%, followed by Energy at +1.14% and Financials at +0.99%. The major averages showed mixed results, with the SPDR S&P 500 ETF Trust (SPY) down 0.06% and the Invesco QQQ Trust down 0.92%, while the Dow Jones Industrial Average ETF rose 0.42%. Notably, the Technology sector lagged, declining by 1.28%, driven by losses in major companies like Oracle and Microsoft. https://www.openbell.ai/news/UCBJF:1792162421609 2026-10-16T14:53:41.609Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Doctor-Working-On-Virtual-Touch-Screen-P.jpg?width=250&height=187 UCB Scores FDA Win With First-Of-Its-Kind Daily Autoinjector for Rare Muscle Disorder UCB SA has received FDA approval for its Zilbrysq autoinjector, the first self-administered, once-daily treatment for generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody-positive. The approval is based on data from three studies, including a Phase 3b study showing a 99.8% complete dose delivery rate. The autoinjector is expected to be commercially available in the first quarter of 2027, complementing UCB's existing gMG portfolio, which includes RYSTIGGO. https://www.openbell.ai/news/CLW:1792162251061 2026-10-16T14:50:51.061Z daily 0.9 https://cdn.brandfetch.io/CLW/w/400/h/400?c=1idopYfmtR7ZKg8QMud RBC Capital Maintains Outperform on Clearwater Paper, Raises Price Target to $23 RBC Capital analyst Matthew McKellar has maintained an Outperform rating on Clearwater Paper (NYSE: CLW) and raised the price target from $21 to $23. This adjustment reflects a positive outlook for the company's performance in the market. https://www.openbell.ai/news/CYTK:1792162194933 2026-10-16T14:49:54.933Z daily 0.9 https://cdn.brandfetch.io/CYTK/w/400/h/400?c=1idopYfmtR7ZKg8QMud William Blair Initiates Coverage On Cytokinetics with Outperform Rating William Blair analyst Alethia Young has initiated coverage on Cytokinetics (NASDAQ: CYTK) with an Outperform rating. This marks a positive outlook for the company in the market. https://www.openbell.ai/news/NVA:1792162092554 2026-10-16T14:48:12.554Z daily 0.9 https://cdn.brandfetch.io/NVA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Spruce Point Capital Raises Concern Over Nova Minerals' Purchase Of Antimony Ore In FY26; Says Its Running Out Of Cash Spruce Point Capital has raised concerns regarding Nova Minerals' acquisition of antimony ore scheduled for fiscal year 2026, highlighting potential financial instability as the company is reportedly running out of cash. The situation may impact Nova Minerals' operational capabilities and future growth prospects. Investors should monitor these developments closely, as they could affect the stock performance of NVA. https://www.openbell.ai/news/KARD:1792162070752 2026-10-16T14:47:50.752Z daily 0.9 https://cdn.brandfetch.io/KARD/w/400/h/400?c=1idopYfmtR7ZKg8QMud William Blair Initiates Coverage On Kardigan with Outperform Rating William Blair analyst Alethia Young has initiated coverage on Kardigan (NASDAQ: KARD) with an Outperform rating. This marks a positive outlook for the company in the market. https://www.openbell.ai/news/KRMN:1792162066229 2026-10-16T14:47:46.229Z daily 0.9 https://cdn.brandfetch.io/KRMN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Karman Holdings shares are trading higher after Macquarie initiated coverage on the stock with an Outperform rating and announced a $65 price target. openbell Financial News https://www.openbell.ai/news/CAS:1792162059501 2026-10-16T14:47:39.501Z daily 0.9 https://cdn.brandfetch.io/CAS/w/400/h/400?c=1idopYfmtR7ZKg8QMud RBC Capital Maintains Outperform on Cascades, Raises Price Target to C$21 RBC Capital analyst Matthew McKellar has maintained an Outperform rating on Cascades (TSX: CAS) and increased the price target from C$18 to C$21. This adjustment reflects a positive outlook for the company. https://www.openbell.ai/news/ETHA:1792162010566 2026-10-16T14:46:50.566Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Eth-Coin-With-Blurred-Candlestick-Chart-.jpg?width=250&height=187 Ethereum ETFs See $60 Million Outflows: Why BlackRock’s ETHA Is Facing Selling Pressure U.S. spot Ethereum ETFs experienced $60.22 million in net outflows on Thursday, marking the second consecutive day of withdrawals, with BlackRock's iShares Ethereum Trust ETF (ETHA) leading the decline at $44.39 million. In contrast, Fidelity's Ethereum Fund (FETH) attracted $2.44 million in inflows, highlighting divergent investor behavior. Despite the outflows, total net assets for U.S. spot Ethereum ETFs remain at $15.29 billion, approximately 5.10% of Ethereum's market capitalization. Investors are closely monitoring Ethereum's upcoming fourth-quarter network upgrade as a potential catalyst for renewed interest in the cryptocurrency.